Sekelj Fures J, Duranovic V, Lenicek Krleza J, Bojanac A, Loncar L, Dakovic I
Diagnostics (Basel). 2024; 14(23).
PMID: 39682553
PMC: 11640429.
DOI: 10.3390/diagnostics14232645.
Hajhashemy Z, Golpour-Hamedani S, Eshaghian N, Sadeghi O, Khorvash F, Askari G
Front Nutr. 2024; 11:1433390.
PMID: 39539367
PMC: 11557489.
DOI: 10.3389/fnut.2024.1433390.
Raggi A, Leonardi M, Arruda M, Caponnetto V, Castaldo M, Coppola G
J Headache Pain. 2024; 25(1):189.
PMID: 39482575
PMC: 11529271.
DOI: 10.1186/s10194-024-01889-x.
Talandashti M, Shahinfar H, Delgarm P, Jazayeri S
Neurol Sci. 2024; 46(2):651-670.
PMID: 39404918
DOI: 10.1007/s10072-024-07794-0.
An Y, Hung K, Liang C, Tsai C, Tsai C, Chen S
J Headache Pain. 2024; 25(1):149.
PMID: 39266962
PMC: 11391721.
DOI: 10.1186/s10194-024-01850-y.
The Intersection of Migraine and Epistaxis: Clinical Observations and Analysis.
Rohatgi S, Gundewar S, Nirhale S, Rao P, Naphade P, Oommen A
Cureus. 2024; 16(7):e65584.
PMID: 39192906
PMC: 11349249.
DOI: 10.7759/cureus.65584.
Effects of Anti-CGRP Monoclonal Antibodies on Neurophysiological and Clinical Outcomes: A Combined Transcranial Magnetic Stimulation and Algometer Study.
Manganotti P, Deodato M, DAcunto L, Biaduzzini F, Garascia G, Granato A
Neurol Int. 2024; 16(4):673-688.
PMID: 39051212
PMC: 11270432.
DOI: 10.3390/neurolint16040051.
Navigating the Neurobiology of Migraine: From Pathways to Potential Therapies.
Tanaka M, Tuka B, Vecsei L
Cells. 2024; 13(13.
PMID: 38994951
PMC: 11240811.
DOI: 10.3390/cells13131098.
Migraine and Its Treatment from the Medicinal Chemistry Perspective.
Pehlivanlar E, Carradori S, Simsek R
ACS Pharmacol Transl Sci. 2024; 7(4):951-966.
PMID: 38633587
PMC: 11020076.
DOI: 10.1021/acsptsci.3c00370.
Calcitonin gene-related peptide: a possible biomarker in migraine patients with patent foramen ovale.
Li C, Yu Y, Li N, Yin Y, Zhang L, Xie K
BMC Neurol. 2024; 24(1):126.
PMID: 38627623
PMC: 11020291.
DOI: 10.1186/s12883-024-03615-1.
Efficacy and safety of eptinezumab for migraine: A systematic review and meta-analysis.
Zhong Y, Wang J, Li H, Yang S, Li X, Gao H
J Res Med Sci. 2024; 28:82.
PMID: 38292336
PMC: 10826853.
DOI: 10.4103/jrms.jrms_306_22.
Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine.
Dermitzakis E, Vikelis M, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P
J Clin Med. 2024; 13(2).
PMID: 38256516
PMC: 10816996.
DOI: 10.3390/jcm13020386.
Double-blind, randomized, placebo-controlled study to evaluate erenumab-specific central effects: an fMRI study.
Basedau H, Peng K, Schellong M, May A
J Headache Pain. 2024; 25(1):5.
PMID: 38195378
PMC: 10775481.
DOI: 10.1186/s10194-023-01709-8.
Xenobiotic Exposure and Migraine-Associated Signaling: A Multimethod Experimental Study Exploring Cellular Assays in Combination with and Mouse Models.
Rasmussen R, Christensen S, Calloe K, Nielsen B, Rehfeld A, Taylor-Clark T
Environ Health Perspect. 2023; 131(11):117003.
PMID: 37909725
PMC: 10619430.
DOI: 10.1289/EHP12413.
Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization study.
Bi Y, Zhu Y, Tang S, Huang Y
J Headache Pain. 2023; 24(1):112.
PMID: 37596566
PMC: 10439594.
DOI: 10.1186/s10194-023-01633-x.
The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN).
Filippi M, Messina R, Bartezaghi M, Cetta I, Colombo B, Grazzi L
J Neurol. 2023; 270(11):5600-5612.
PMID: 37550498
PMC: 10576673.
DOI: 10.1007/s00415-023-11879-9.
Association Between Migraine and Ischemic Cardio-Cerebrovascular Disease (CCVD) and Effects of Triptans and Ergotamine on the Risk of Ischemic CCVD in Patients with Migraine in the Korean NHIS-HEALS Cohort.
Kim Y, Shin S, Lee J, Kim Y, You H, Kim J
Clin Drug Investig. 2023; 43(7):541-550.
PMID: 37460781
DOI: 10.1007/s40261-023-01290-7.
Dysfunction of inhibitory interneurons contributes to synaptic plasticity via GABABR-pNR2B signaling in a chronic migraine rat model.
Zeng X, Niu Y, Qin G, Zhang D, Chen L
Front Mol Neurosci. 2023; 16:1142072.
PMID: 37324588
PMC: 10265202.
DOI: 10.3389/fnmol.2023.1142072.
Research Progress in Calcitonin Gene-Related Peptide and Bone Repair.
Wang Q, Qin H, Deng J, Xu H, Liu S, Weng J
Biomolecules. 2023; 13(5).
PMID: 37238709
PMC: 10216440.
DOI: 10.3390/biom13050838.
Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study.
Straube A, Broessner G, Gaul C, Hamann X, Hipp J, Kraya T
J Headache Pain. 2023; 24(1):59.
PMID: 37221478
PMC: 10207758.
DOI: 10.1186/s10194-023-01593-2.